

Literatura

ACOG 57th Annual Clinical Meeting. Chicago, Illinois 2009. [Citace 24. 1. 2013]. Available from: <http://www.acog.org/acm/pdf/postersMon.pdf>,

Ågren UM, Anttila M, Mäenpää-Liukko K et al. Effects of a monophasic combined oral contraceptive containing norgestrel acetate and 17 β -oestradiol compared with one containing levonorgestrel and ethinylestradiol on haemostasis, lipids and carbohydrate metabolism. *Eur J Contracept Reprod Health Care* 2011 Dec; 16(6): 444–457.

Ahrendt HJ, Makalova D, Parke S et al. Bleeding pattern and cycle control with an estradiol-based oral contraceptive: a seven-cycle, randomized comparative trial of estradiol valerate/dienogest and ethinyl estradiol/levonorgestrel. *Contraception* 2009; 80: 436–444.

- Allais G, Benedetto C. Update on menstrual migraine: from clinical aspects to therapeutic struggle. *Neurol Sci* 2004; 25(Suppl 3): S229–S231.
- Anderson FD, Gibbons W, Portman D. Long-term safety of an extended-cycle oral contraceptive (Seasonale): a 2-year multicenter open-label extension trial. *Am J Obstet Gynecol* 2006; 195: 92–96.
- Anderson FD, Hait H, Hsiu J et al. Endometrial microstructure following long-term use of a 91-day extended cycle oral contraceptive regimen. *Contraception* 2005; 71: 55–59.
- Anderson FD, Hait H. The Seasonale-301 Study Group. A multicenter, randomized study of an extended cycle oral contraceptive. *Contraception* 2003; 68: 89–96.
- Archer DF, Stanczyk FZ, Rubin A et al. Ethinyl estradiol and levonorgestrel pharmacokinetics with a low-dose transdermal contraceptive delivery system, AG200-15: a randomized controlled trial. *Contraception* 2012 Jun; 85(6): 595–601.
- Brache V, Payán LJ, Faundes A. Current status of contraceptive vaginal rings. *Contraception*. 2013 Mar; 87(3): 264–272. doi: 10.1016/j.contraception.2012.08.037. Epub 2012 Oct 4. PMID: 23040125. ClinicalTrials.gov. A Multi-center, Open-label, Randomized, Parallel Group Study to Evaluate Pharmacokinetic Profile, Effects on the Mechanisms of Contraceptive Efficacy and Safety of Two Progestin-only Patches Containing Different Doses of Levonorgestrel (LNG) (CCN009) [Citace 23. 1. 2013]. Dostupné na: <http://clinicaltrials.gov/ct2/show/NCT01166412>.
- Coelingh Bennink HJ, Skouby S, Bouchard P et al. Ovulation inhibition by estetrol in an in vivo model. *Contraception* 2008; 77: 186–190.
- Coffee AL, Kuehl TJ, Willis S et al. Oral contraceptive and premenstrual symptoms: comparison of a 21/7 and extended regimen. *Am J Obstet Gynecol* 2006; 195: 1311–1319.
- Drug information online. BioSante Pharmaceuticals Announces Positive Oral Contraceptive Clinical Results. [Citace 15. 1. 2013]. Available from: http://www.drugs.com/clinical_trials/biosante-pharmaceuticals-announces-positive-oral-contraceptive-clinical-results-5455.html
- Effects on ovarian function of the combined oral contraceptive NOMAC-E2 compared to COC containing DRSP/EE (292003). [Citace 15. 1. 2013]. Available from: <http://clinicaltrials.gov/ct2/show/study/NCT00511433>
- Fraser IS, Weisberg E, Kumar N et al. An initial pharmacokinetic study with a Metered Dose Transdermal System for delivery of the progestogen Nestorone as a possible future contraceptive. *Contraception* 2007; 76: 432–438.
- Fruzzetti F, Fidecicchi T, Montt Guevara MM, Simoncini T. Estetrol: A New Choice for Contraception. *J Clin Med* 2021 Nov 29; 10(23): 5625.
- Garza-Flores J, Hall PE, Perez-Palacios G. Long-acting hormonal contraceptives for women. *J Steroid Biochem Mol Biol* 1991; 40: 697–704.
- Gonzalo IT, Swerdloff RS, Nelson AL et al. Levonorgestrel implants (Norplant II) for male contraception clinical trials: combination with transdermal and injectable testosterone. *J Clin Endocrinol Metab* 2002; 87(8): 3562.
- Grimes DA, Godwin AJ, Rubun A et al. Ovulation and follicular development associated with three low/dose oral contraceptives> a randomiyed controlled trial. *Obstet Gynecol* 1994; 83: 29–34.
- Grimes DA, Lopez LM, Gallo MF et al. Steroid hormones for contraception in men. *Cochrane Database Syst Rev* 2012 Mar 14; 3: CD004316. doi: 10.1002/14651858. CD004316.pub4.
- Heger-Mahn D, Warlimont C, Faustmann T et al. Combined ethinylestradiol/gestodene contraceptive patch: two-center, open-label study of ovulation inhibition.

- acceptability and safety over two cycles in female volunteers. *Eur J Contracept Reprod Health Care* 2004; 9: 173–181.
- Hernadi L, Marr J, Trummer D et al. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. *Contraception* 2009; 80: 18–24.
- Holinka CF, Diczfalussy E, Coelingh Bennink HJ. Estetrol: A unique steroid in human pregnancy. *J Steroid Biochem Mol Biol* 2008; 110(1–2): 138–143.
- Chabbert-Buffet N, Ouzounian S, Kairis AP et al. Contraceptive applications of progesterone receptor modulators. *Eur J Contracept Reprod Health Care* 2008; 13: 222–230.
- Chetrite GS, Thomas JL, Shiels-Botella J et al. Control of sulfatase activity by norgestrel acetate in normal and cancerous human breast tissues. *Anticancer Res* 2005; 25: 2827–2830.
- Christin-Maitre S, Laroche E, Bricaire L. A new contraceptive pill containing 17beta-estradiol and norgestrel acetate. *Women's health* 2013; 9(1): 13–23.
- Ilani N, Roth MY, Amory JK et al. A new combination of testosterone and norethone transdermal gels for male hormonal contraception. *The Journal of clinical endocrinology and metabolism* 2012; 97: 3476–3486.
- Jensen JT, Archer DF. Evaluation of continuous regimen of levonorgestrel/ethinylestradiol for contraception and control of menstrual symptoms. *Expert Opin Pharmacother* 2008; 9: 319–327.
- Jesam C, Salvatierra AM, Schwartz JL, et al. Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. *Hum Reprod* 2010; 25: 368–373.
- Jütte R. *Contraception A History*. Cambridge: Polity, 2008, 288 pp. ISBN 0745632718.
- Kaunitz AM, Portman DJ, Hait H et al. Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive. *Contraception* 2009; 79: 350–355.
- Kweiczen M, Edelman A, Nichols MD et al. Bleeding patterns and patient acceptability of standard or continuous dosing regimens of low-dose oral contraceptive: a randomized trial. *Contraception* 2003; 67: 9–13.
- Lal J, Nitynand S, Asthana OP et al. Optimization of contraceptive dosage regimen of Centchroman. *Contraception* 2001; 63: 47–51.
- Lello S. Norgestrel acetate: clinical pharmacology. *Minerva Ginecol* 2009; 61: 459–463.
- Machado RB, Fabrini P, Cruz AM et al. Clinical and metabolic aspects of the continuous use of a contraceptive association of ethinyl estradiol (30 µg) and gestodene (75 µg). *Contraception* 2004; 70: 365–370.
- Okajima ST, Archer DF, Ellman H et al. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 µg (Loestrin 24 Fe). *Contraception* 2007; 75: 16–22.
- Nath A, Sitruk-Ware R. Progesterone vaginal ring for contraceptive use during lactation. *Contraception* 2010; 82: 428–434.
- Naz RK, Gupta SK, Gupta JC et al. Recent advances in contraceptive vaccine development: a mini-review. *Hum Reprod* 2005; 20(12): 3271.
- Nelson A, Sampson-Landers C, Parke S et al. Efficacy of Estradiol Valerate/Dienogest OC: Results of 3 Large Studies in North America and Europe. *Gynecol Endocrinol* 2012 May; 28(5): 400–408.

- Page ST, Amory JK, Anawalt BD et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. *J Clin Endocrinol Metab* 2006; 91(11): 4374.
- Page ST, Amory JK, Anawalt BD et al. Testosterone gel combined with depomedroxyprogesterone acetate is an effective male hormonal contraceptive regimen and is not enhanced by the addition of a GnRH antagonist. *J Clin Endocrinol Metab* 2006; 91(11): 4374.
- Sachdeva V, Bai Y, Kydonieus A et al. Formulation and optimization of desogestrel transdermal contraceptive patch using crystallization studies. *Int J Pharm.* 2012 Dec 20; 441(1–2): 9–18.
- Singh MM. Centchroman, a selective estrogen receptor modulator, as a contraceptive and for the management of hormone-related clinical disorders. *Med Res Rev* 2001; 21: 302–347.
- Sitruk-Ware RL, Menard J, Rad M, et al. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen. *Contraception* 2007; 75: 430–437.
- Sitruk-Ware R, Nath A, Mishell DR Jr. Contraception technology: past, present and future. *Contraception* 2013 Mar; 87(3): 319–330.
- Sitruk-Ware R. New delivery systems in contraception. [přednáška].
Budapešť: 15. kongres Evropské společnosti pro antikoncepci a plánované rodičovství (ESC), 9.–12. 5. 2018.
- Spona J, Binder N, Höschen K et al. Suppression of ovarian function by a combined oral contraceptive containing 0.02 mg ethinyl estradiol and 2 mg chlormadinone acetate given in a 24/4-day intake regimen over three cycles. *Fertil Steril* 2010; 94(4): 1195–1201.
- Stouffer RL, XU F, Duffy DM. Molecular control of ovulation and luteinization in the primate follicle. *Fron Biosci* 2007; 12: 297–307.
- Sulak PJ, Kuehl TJ, Coffee A et al. Prospektive analysis of occurrence and management of breakthrough bleeding during an extended oral contraceptive regimen. *Am J Obstet Gynecol* 2006; 195: 935–941.
- Sulak PJ, Kuehl TJ, Ortiz M et al. Acceptance of altering the standard 21-day/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms. *Am J Obstet Gynecol* 2002; 186: 1142–1149.
- Sulak PJ, Scow RD, Preece C et al. Hormone withdrawal symptoms in oral contraceptive users. *Obstet Gynecol* 2000; 95: 261–266.
- Sulak PJ, Willis S, Kueh, TJ et al. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval. *Headache* 2007; 47: 27–37.
- Sulak PJ. Continuous oral contraception: changing times. *Best Practice and Research Obstetrics and Gynaecology* 2008; 22: 355–374.
- Sullivan H, Furniss H, Spona J et al. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 µg) and ethinyl estradiol (15 µg) on ovarian activity. *Fertil Steril* 1999; 72: 115–120.
- Suvisaari J, Moo-Young A, Juhakoski A et al. Pharmacokinetics of 7 alpha-methyl-19-nortestosterone (MENT) delivery using subdermal implants in healthy men. *Contraception*. 1999; 60(5): 299.
- Vandever MA, Kuehl TJ, Sulak PJ et al. Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens. *Contraception* 2008; 77: 162–170.

Vercellini P, Frontino G, DeGiorgio O et al. Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhoea that does not respond to a cyclic pill regimen. *Fertil Steril* 2003; 80: 560–563.

Wagstaff AJ. Continuous-use ethinylestradiol/levonorgestrel 20microg/90microg: as an oral contraceptive. *Drugs* 2007; 67: 2473–2477.

Yonkers KA, Brown C, Pearlstein TB et al. Efficacy of a new low-dose oral contraceptive with drospirenone in premenstrual dysphoric disorder. *Obstet Gynecol* 2005; 106: 492–501.

Zurdo Schroeder I, Franke P, Schaefer UF et al. Delivery of ethinylestradiol from film forming polymeric solutions across human epidermis in vitro and in vivo in pigs. *Control Release*. 2007; 118: 196–203.